Note this product is more clinically effective and safer than Design for health Foresterol and Red Yeast Rice.
Suggested Use: Take two small capsules daily with food or as directed by your healthcare provider. No need to take Co-QH (Co-q10) with this product.
Note: Unlike regular RYR which are provided in large capsules and usually 3 is a serving, this patented and concentrated form is provided in two small capsules (the size of our Vitamin D3) and thus easy to swallow and much smaller than other brands. This product also does not contain Monacolin K and is citrinin-free (common mycotoxin found in many generic red yeast rice products).
Monaflavin RYR is the Next Generation of Red Yeast Rice (RYR). With over 28 patents on the products key ingredient called Ankascin 568-R and over 120 scientific publications, it has been approved as a New Dietary Ingredient (NDI) by FDA which means they had to submit safety and clinical studies for efficacy review to FDA before they could bring it to the marketplace. (1) Unlike all the other Red Yeast Rice products on the market that contain monacolin K, the component that had a "statin-like" effect along with its side effects, this product DOES NOT contain monacolin K. and does NOT cause any of the common side effects like muscle pain or the need to add Co-q10 with it.
Monaflavin RYR contains the patented Ankascin 568-R which is an extract fermented M purpureus that contains the active compounds monascin (2.8%) and ankaflavin (0.9%) with NO monacolin K or citrinin. Two capsules of Monaflavin provides 110 mg of Ankascin 568-R.
In a randomized, double-blind, placebo-controlled trial, subjects (N=21) with a clinical diagnosis of hypertension were given two capsules of Monoflavin RYR (Ankascin 568-R/day containing 110 mg of RYR extract with 3 mg of monascin and 1.5 mg of ankaflavin per capsule) for 8 weeks. Subjects in the test group had a significantly reduced systolic and diastolic blood pressure following 4 weeks of administration, and the results were maintained until the end of the 8-week period. Additionally, the treatment group demonstrated a significant improvement in serum lipid profile with reduced levels of total cholesterol, trigylcerides and LDL-C and no significant rhabdomyolysis or impairment of the metabolic or physiologic functions of the liver or kidney.(2)
In another randomized, double-blind, placebo-controlled trial, subjects (N=40) with borderline elevated cholesterol were given 110 mg of Monaflavin RYR (Anakascin 568-R/day) for an 8 -week duration. A significant reduction was shown in serum cholesterol (11.9%) and LDL-C (19%) in as little as 4 weeks. In a 4-week washout period following the treatment phase, levels reverted back to baseline for both total cholesterol and LDL-C.(3)
An additional randomized, double-blind, placebo-controlled study explored the effect of Monaflavin RYR (Ankascin 568-R) on blood glucose regulation. Subjects (N=39) with elevated fasting glucose and HBA1c levels were given 220 mg of Monaflavin RYR (Ankascin 568-R) daily for 12 weeks. The results showed a significant reduction in serum blood glucose as well as total cholesterol and LDL-C levels in the test group subjects after 6 weeks. The authors noted that Monaflavin RYR (Ankascin 568-R) as a potentially useful ingredient for the regulation of blood glucose and the support of cardiovascular health.(4)
1). ANKASCIN 568-R. Sunway Biotech Co. LTD.; 2017:1-15. Accessed Feb 2021. https://sunway.cc/en/white-paper%ef%bc%8dthe-ankascin-568-r-safe-effective-and approved-red-yeast-rice-extract/
2) Chen CL, Tseng JH, Pan TM, et al. Chin J Physiol. 2017;60(3):158-165. doi:10.4077.CJP.2017/BAF452
3) Li SF, Wang YR, Shen YC, et al. J Food Drug Anal. 2018; 26)1): 393-400. doi:10.1016/j.jfda.2017.04.006
4) Wang YR, Liu SF, Shen YC, et al. J Food Drug Anal. 2017; 25(2):409-416. doi:10.1016/j.jfda.2016.06.011